Previous 10 | Next 10 |
Jerry Durso Appointed CEO Effective January 1, 2021 ; Founder, President and CEO Mark Pruzansk i to Continue as Board Member and Advis o r NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (N...
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President a...
David Einhorn's 13F stock portfolio value increased from $922M to $1.22B this quarter. Greenlight added SYNNEX, NCR, Twitter, Intel, and Ingredion, while reducing AerCap Holdings. The short position in Tesla through puts was increased during the quarter. The largest three position...
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced multiple new analyses supporting the u...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Intercept Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Q3 2020 Earnings Call Nov 9, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Intercept Pharmaceuticals Inc (ICPT) Q3 2020 Earnings Call Tra...
Intercept Pharmaceuticals, Inc. (ICPT) Q3 2020 Earnings Conference Call November 6, 2020 08:30 ET Company Participants Lisa DeFrancesco - Head of Investor Relations Mark Pruzanski - Chief Executive Officer Jerome Durso - Chief Operating Officer Sandip Kapadia - Chief Financial Officer Confere...
Intercept Pharmaceuticals (NASDAQ: ICPT) really needed some good news. Its shares have plunged by more than 70% year to date, with most of the decline coming after the Food and Drug Administration gave a thumbs-down to obeticholic acid (OCA) as a treatment for non-alcoholic steatohe...
Intercept Pharma ([[ICPT]] +7.6%) Q3 results:Ocaliva net sales: $79.5M (+29.0%).Net loss: ($65.5M) (+21.6%); loss/share: ($1.92) (+22.4%) vs consensus of ($1.94).Cash, cash equivalents, restricted cash and investment debt securities, available for sale of $496.8M.Productive Type A Meetin...
Intercept Pharma (ICPT): Q3 GAAP EPS of -$2.01 misses by $0.04.Revenue of $79.52M (+28.4% Y/Y) beats by $0.92M.2020 guidance: Ocaliva net sales: $310M - 320M from $300M - 320M.Press Release For further details see: Intercept Pharma EPS misses by $0.04, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...